|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hughes KS, Rosenstein RB, Songhorabodi S,
et al: Resection of the liver for colorectal carcinoma metastases.
A multi-institutional study of long-term survivors. Dis Colon
Rectum. 31:1–4. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scheele J, Stang R, Altendorf-Hofmann A
and Paul M: Resection of colorectal liver metastases. World J Surg.
19:59–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato T, Yasui K, Hirai T, et al:
Therapeutic results for hepatic metastasis of colorectal cancer
with special reference to effectiveness of hepatectomy: analysis of
prognostic factors for 763 cases recorded at 18 institutions. Dis
Colon Rectum. 46:S22–S31. 2003.
|
|
6
|
Yamada H, Katoh H, Kondo S, Okushiba S and
Morikawa T: Repeat hepatectomy for recurrent hepatic metastases
from colorectal cancer. Hepatogastroenterology. 48:828–830.
2001.PubMed/NCBI
|
|
7
|
Scheer MG, Sloots CE, van der Wilt GJ and
Ruers TJ: Management of patients with asymptomatic colorectal
cancer and synchronous irresectable metastases. Ann Oncol.
19:1829–1835. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dy GK, Hobday TJ, Nelson G, et al:
Long-term survivors of metastatic colorectal cancer treated with
systemic chemotherapy alone: north central cancer treatment group
review of 3811 patients, n0144. Clin Colorectal Cancer. 8:88–93.
2009. View Article : Google Scholar
|
|
9
|
Venook A: Critical evaluation of current
treatments in metastatic colorectal cancer. Oncologist. 10:250–261.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cabrera C, Artacho R and Gimenez R:
Beneficial effects of green tea: a review. J Am Coll Nutr.
25:79–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji BT, Chow WH, Hsing AW, et al: Green tea
consumption and the risk of pancreatic and colorectal cancers. Int
J Cancer. 70:255–258. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang G, Shu XO, Li H, et al: Prospective
cohort study of green tea consumption and colorectal cancer risk in
women. Cancer Epidemiol Biomarkers Prev. 16:1219–1223. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cabrera C, Gimenez R and Lopez MC:
Determination of tea components with antioxidant activity. J Agric
Food Chem. 51:4427–4435. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Du GJ, Zhang Z, Wen XD, et al:
Epigallocatechin gallate (EGCG) is the most effective cancer
chemopreventive polyphenol in green tea. Nutrients. 4:1679–1691.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimizu M, Adachi S, Masuda M, Kozawa O
and Moriwaki H: Cancer chemoprevention with green tea catechins by
targeting receptor tyrosine kinases. Mol Nutr Food Res. 55:832–843.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen C, Shen G, Hebbar V, Hu R, Owuor ED
and Kong AN: Epigallocatechin-3-gallate-induced stress signals in
HT-29 human colon adenocarcinoma cells. Carcinogenesis.
24:1369–1378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shimizu M, Shirakami Y, Sakai H, et al:
(−)-Epigallocatechin gallate inhibits growth and activation of the
VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol
Interact. 185:247–252. 2010.
|
|
18
|
Tran PL, Kim SA, Choi HS, Yoon JH and Ahn
SG: Epigallocatechin-3-gallate suppresses the expression of HSP70
and HSP90 and exhibits anti-tumor activity in vitro and
in vivo. BMC Cancer. 10:2762010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin H, Gong W, Zhang C and Wang S:
Epigallocatechin gallate inhibits the proliferation of colorectal
cancer cells by regulating Notch signaling. Onco Targets Ther.
6:145–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoffman RM: Orthotopic metastatic mouse
models for anticancer drug discovery and evaluation: a bridge to
the clinic. Invest New Drugs. 17:343–359. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishida N, Yano H, Nishida T, Kamura T and
Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag.
2:213–219. 2006. View Article : Google Scholar
|
|
22
|
Shih T and Lindley C: Bevacizumab: an
angiogenesis inhibitor for the treatment of solid malignancies.
Clin Ther. 28:1779–1802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang BH and Liu LZ: AKT signaling in
regulating angiogenesis. Curr Cancer Drug Targets. 8:19–26. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zarubin T and Han J: Activation and
signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi Y and Gaestel M: In the cellular
garden of forking paths: how p38 MAPKs signal for downstream
assistance. Biol Chem. 383:1519–1536. 2002.PubMed/NCBI
|
|
27
|
Rudolf E, Kralova V, Rudolf K and John S:
The role of p38 in irinotecan-induced DNA damage and apoptosis of
colon cancer cells. Mutat Res. 741–742:27–34. 2013.PubMed/NCBI
|
|
28
|
Liu HF, Hu HC and Chao JI: Oxaliplatin
down-regulates survivin by p38 MAP kinase and proteasome in human
colon cancer cells. Chem Biol Interact. 188:535–545. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mazzanti G, Menniti-Ippolito F, Moro PA,
et al: Hepatotoxicity from green tea: a review of the literature
and two unpublished cases. Eur J Clin Pharmacol. 65:331–341. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lambert JD, Kennett MJ, Sang S, Reuhl KR,
Ju J and Yang CS: Hepatotoxicity of high oral dose
(−)-epigallocatechin-3-gallate in mice. Food Chem Toxicol.
48:409–416. 2010.
|
|
31
|
Shimizu M, Deguchi A, Lim JT, Moriwaki H,
Kopelovich L and Weinstein IB: (−)-Epigallocatechin gallate and
polyphenon E inhibit growth and activation of the epidermal growth
factor receptor and human epidermal growth factor receptor-2
signaling pathways in human colon cancer cells. Clin Cancer Res.
11:2735–2746. 2005.
|
|
32
|
Shimizu M, Shirakami Y, Sakai H, et al:
EGCG inhibits activation of the insulin-like growth factor
(IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
Cancer Lett. 262:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yunos NM, Beale P, Yu JQ and Huq F:
Synergism from the combination of oxaliplatin with selected
phytochemicals in human ovarian cancer cell lines. Anticancer Res.
31:4283–4289. 2011.PubMed/NCBI
|
|
34
|
Yang XW, Wang XL, Cao LQ, et al: Green tea
polyphenol epigallocatechin-3-gallate enhances
5-fluorouracil-induced cell growth inhibition of hepatocellular
carcinoma cells. Hepatol Res. 42:494–501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu H, Xin Y, Xu C and Xiao Y: Capecitabine
combined with (−)-epigallocatechin-3-gallate inhibits angiogenesis
and tumor growth in nude mice with gastric cancer xenografts. Exp
Ther Med. 3:650–654. 2012.
|
|
36
|
Shimizu M, Fukutomi Y, Ninomiya M, et al:
Green tea extracts for the prevention of metachronous colorectal
adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev.
17:3020–3025. 2008. View Article : Google Scholar : PubMed/NCBI
|
